跳至主要内容
临床试验/ACTRN12607000181404
ACTRN12607000181404进行中(未招募)2 期

In patients with NAION (Non-arteritic anterior ischemic optic neuropathy), is Memantine as good as or better than placebo for improving visual functions?

Tehran University of Medical sciences0 个研究点目标入组 44 人开始时间: 2007年3月26日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 o limit(—)
性别
All

入选标准

  • Unilateral acute onset of painless visual loss, localized or generalized edema and paleness of the optic nerve head, flame shaped hemorrhages, arterial narrowing without venous congestion and RAPD (relative afferent pupillary defect) in acute phase (=8 weeks) along with visual field defect consistent with non arteritic AION in perimetry.

排除标准

  • Pregnancy and breast feeding, complete optic disc atrophy that other etiologies were suggested, presence of systemic signs and symptoms such as fever, headache… consistent with arteritic AION, drug history such as anti-convulsants, barbiturates, neuroleptics, Amantadine hydrochlorothiazids and history of renal insufficiency.

研究者

相似试验